Vascular, diabetes surge ahead at Abbott:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories reported a 14.4% increase in sales of medical products in the fourth quarter, with its vascular devices and diabetes care units providing much of the impetus. The company did not disclose total medical product sales, but said diabetes care was up by 71% to $242m in the quarter, helped by the purchase of TheraSense. Vascular device sales rose by 12% to $60m. Fourth-quarter diagnostic sales rose by 15% to $927m. Group sales rose by 16% to $5.7bn, with earnings up 3% to $975m. Full-year sales and earnings were $20bn (+14%) and $3.2bn (+18%), respectively.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.